Deutsch English Français

Contact

EP2895168

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2895168

EP2895168 - TETRANDRINE PHARMACEUTICAL FORMULATIONS AND METHOD [Right-click to bookmark this link]
Status	The application has been refused Status updated on 19.09.2018 Database last updated on 19.10.2024
Former	Examination is in progress Status updated on 07.04.2017
Most recent event Tooltip	04.01.2019	Refusal of application	published on 06.02.2019 [2019/06]
Applicant(s)	For all designated states CBA Pharma Inc. 670 Perimeter Drive Lexington, KY 40517 / US
	[2015/30]
Inventor(s)	01 / CARROLL, Ron, D. 7295 Wakefield Drive Fayetteville, NY 13066-9769 / US
	[2015/30]
Representative(s)	FRKelly Waterways House Grand Canal Quay Dublin D02 PD39 / IE
	[N/P]
Former [2015/30]	O'Connell, Maura FRKelly 27 Clyde Road Ballsbridge Dublin 4 / IE
Application number, filing date	13836799.0	12.09.2013
	WO2013US59447
Priority number, date	US201261700701P	13.09.2012 Original published format: US 201261700701 P
	[2015/30]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	WO2014043336
	Date:	20.03.2014
	Language:	EN
	[2014/12]
	Type:	A2 Application without search report
	No.:	EP2895168
	Date:	22.07.2015
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 20.03.2014 takes the place of the publication of the European patent application.
	[2015/30]
Search report(s)	International search report - published on:	US	23.07.2015
	(Supplementary) European search report - dispatched on:	EP	03.08.2016
Classification	IPC:	A61K31/4745, A61P35/00	[2016/22]
	CPC:	A61K31/4745 (EP,MX,US); A61K9/4866 (EP,MX,US); A61P33/06 (EP); A61P35/00 (EP); A61K31/4741 (EP,MX,US); A61K47/36 (EP,MX,US); (+) A61K47/38 (EP,MX,US) (-)
	Former IPC [2015/30]	A61K31/4745
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/09]
Former [2015/30]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Title	German:	TETRANDRINARZNEIMITTELFORMULIERUNGEN UND VERFAHREN	[2015/30]
	English:	TETRANDRINE PHARMACEUTICAL FORMULATIONS AND METHOD	[2015/30]
	French:	FORMULATIONS PHARMACEUTIQUES DE TÉTRANDRINE ET PROCÉDÉ ASSOCIÉ	[2015/30]
Entry into regional phase	10.04.2015	National basic fee paid
	10.04.2015	Search fee paid
Examination procedure	22.01.2016	Examination requested [2016/09]
	14.02.2017	Amendment by applicant (claims and/or description)
	11.04.2017	Despatch of a communication from the examining division (Time limit: M06)
	06.10.2017	Reply to a communication from the examining division
	30.08.2018	Application refused, date of legal effect [2019/06]
	13.09.2018	Cancellation of oral proceeding that was planned for 31.10.2018
	20.09.2018	Despatch of communication that the application is refused, reason: substantive examination [2019/06]
	31.10.2018	Date of oral proceedings (cancelled)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 11.04.2017
Fees paid	Renewal fee
	31.03.2016	Renewal fee patent year 03
	22.02.2017	Renewal fee patent year 04
	25.09.2017	Renewal fee patent year 05
	Penalty fee
	Additional fee for renewal fee
	30.09.2015	03 M06 Fee paid on 31.03.2016
	30.09.2016	04 M06 Fee paid on 22.02.2017
	30.09.2018	06 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[Y]EP2420496 (NEURON BIOPHARMA SA [ES]) [Y] 1-4,9,10 * example 20 *
		[Y] - YI-CHAO HSU ET AL, "Antifibrotic effects of tetrandrine on hepatic stellate cells and rats with liver fibrosis", JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, AU, (20070101), vol. 22, no. 1, doi:10.1111/j.1440-1746.2006.04361.x, ISSN 0815-9319, pages 99 - 111, XP055267716 [Y] 1-4,9,10 * abstract; p. 102, chapter "Chemicals and drugs" * DOI: http://dx.doi.org/10.1111/j.1440-1746.2006.04361.x
		[Y] - YAN C ET AL, "Tetrandrine-induced apoptosis in rat primary hepatocytes is initiated from mitochondria: Caspases and Endonuclease G (Endo G) pathway", TOXICOLOGY, LIMERICK, IR, vol. 218, no. 1, ISSN 0300-483X, (20060120), pages 1 - 12, (20060120), XP027919251 [Y] 1-4,9,10 * abstract; chapter 2.2. "Animals and treatments" *
	International search	[Y]US6911454 (VAN DYKE KNOX [US]);
		[Y]US2008268036 (GUY ALEN [US], et al);
		[Y]US5025020 (VAN DYKE KNOX [US]);
		[Y]US6528519 (VAN DYKE KNOX [US]);
		[Y]US6124315 (VAN DYKE KNOX [US]);
		[Y]US6962927 (VAN DYKE KNOX [US])
		[Y] - XIAOYAN ET AL., "Preparation of chitosan gelatin scaffold containing tetrandrine-loaded nano-aggregates and its controlled release behavior", INTERNATIONAL JOURNAL OF PHARMACEUTICS, (2008), vol. 350, pages 257 - 264, XP022435783 DOI: http://dx.doi.org/10.1016/j.ijpharm.2007.09.008

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p